 |
|
New clinical trial for patients with asbestos-associated lung cancer
June 26, 2008Investigational therapy may help avoid lung removal surgery for patients with pleural mesothelioma
The Mesothelioma Center within the Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian Hospital and Columbia University Medical Center is now recruiting patients for a clinical research study of a new targeted radiation and chemotherapy protocol for pleural mesothelioma, a cancer of the lung's lining that is almost always caused by previous exposure to asbestos.
The standard treatment for pleural mesothelioma is currently surgery to remove the patient's lung - a potentially debilitating consequence.
"Current surgical and chemotherapy treatments of patients with malignant pleural mesothelioma are unsatisfactory, and have not been shown to significantly prolong survival. In this study, we will investigate whether a combination of chemotherapy and radiation targeted directly at the lung's lining can improve outcomes while avoiding surgery," says Dr. Robert Taub, the study's principal investigator, director of the Mesothelioma Center at NewYork-Presbyterian/Columbia and professor of clinical medicine at Columbia University College of Physicians and Surgeons. "In addition, this approach has shown to have minimal toxic side effects compared to systemic chemotherapy."
"This trial is also significant because our center is the only one nationwide that is offering this experimental therapy to treat pleural mesothelioma," added Dr. Taub. "We are very focused on offering these patients the best treatment that medical technology can offer while simultaneously working to preserve quality of life."
Researchers also anticipate that the radiation therapy will kill the cancer cells on surface of the lung while sparing other parts of the lung and surrounding vital tissues.
"Delivery of radiation therapy directly into the pleural cavity is a strategy that has been employed since 1945. Today, direct injection of radioactive isotope P-32 may prove to be a significant and effective therapeutic approach for selected mesothelioma patients," adds Dr. Rashid Fawwaz, study co-investigator, radiologist at NewYork-Presbyterian/Columbia and professor of clinical radiology at Columbia University College of Physicians and Surgeons.
"Overall, it is hoped that this study will decrease the need for patients to undergo radical surgery," states Dr. Joshua Sonett, study co-investigator, chief of general thoracic surgery, surgical director of the Lung Transplant Program and surgical director of the High-Risk Lung Assessment Program at NewYork-Presbyterian/Columbia and professor of clinical surgery at Columbia University College of Physicians and Surgeons.
Participating patients will receive several rounds of targeted chemotherapy using the drugs cisplatin and doxorubicin via surgically implanted catheters. Some patients will be randomly selected to receive additional systemic (intravenous) chemotherapy using the drugs cisplatin and pemetrexed. All patients will receive targeted radiotherapy using the P-32 radioisotope. Patients may elect to receive additional surgical treatment, including removal of the affected lung lining or lung. Subsequently, patients will be offered outpatient systemic chemotherapy with cisplatin and pemetrexed.
The investigators previously led a prospective study that employed a similar protocol for patients with pleural mesothelioma as well as those with the more retractable sarcomatous disease. Completed in 2002, the study reported a median survival of 70 months, and a three-year survival of 67 percent (American Journal of Clinical Oncology, February 2008).
New York- Presbyterian Hospital/Columbia University Medical Center
"Current surgical and chemotherapy treatments of patients with malignant pleural mesothelioma are unsatisfactory, and have not been shown to significantly prolong survival. In this study, we will investigate whether a combination of chemotherapy and radiation targeted directly at the lung's lining can improve outcomes while avoiding surgery," says Dr. Robert Taub, the study's principal investigator, director of the Mesothelioma Center at NewYork-Presbyterian/Columbia and professor of clinical medicine at Columbia University College of Physicians and Surgeons. "In addition, this approach has shown to have minimal toxic side effects compared to systemic chemotherapy."
"This trial is also significant because our center is the only one nationwide that is offering this experimental therapy to treat pleural mesothelioma," added Dr. Taub. "We are very focused on offering these patients the best treatment that medical technology can offer while simultaneously working to preserve quality of life."
Researchers also anticipate that the radiation therapy will kill the cancer cells on surface of the lung while sparing other parts of the lung and surrounding vital tissues.
"Delivery of radiation therapy directly into the pleural cavity is a strategy that has been employed since 1945. Today, direct injection of radioactive isotope P-32 may prove to be a significant and effective therapeutic approach for selected mesothelioma patients," adds Dr. Rashid Fawwaz, study co-investigator, radiologist at NewYork-Presbyterian/Columbia and professor of clinical radiology at Columbia University College of Physicians and Surgeons.
"Overall, it is hoped that this study will decrease the need for patients to undergo radical surgery," states Dr. Joshua Sonett, study co-investigator, chief of general thoracic surgery, surgical director of the Lung Transplant Program and surgical director of the High-Risk Lung Assessment Program at NewYork-Presbyterian/Columbia and professor of clinical surgery at Columbia University College of Physicians and Surgeons.
Participating patients will receive several rounds of targeted chemotherapy using the drugs cisplatin and doxorubicin via surgically implanted catheters. Some patients will be randomly selected to receive additional systemic (intravenous) chemotherapy using the drugs cisplatin and pemetrexed. All patients will receive targeted radiotherapy using the P-32 radioisotope. Patients may elect to receive additional surgical treatment, including removal of the affected lung lining or lung. Subsequently, patients will be offered outpatient systemic chemotherapy with cisplatin and pemetrexed.
The investigators previously led a prospective study that employed a similar protocol for patients with pleural mesothelioma as well as those with the more retractable sarcomatous disease. Completed in 2002, the study reported a median survival of 70 months, and a three-year survival of 67 percent (American Journal of Clinical Oncology, February 2008).
New York- Presbyterian Hospital/Columbia University Medical Center
Mesothelioma Current Events and Mesothelioma News RSSStudy shows how carbon nanotubes can affect lining of the lungs
Carbon nanotubes are being considered for use in everything from sports equipment to medical applications, but a great deal remains unknown about whether these materials cause respiratory or other health problems.
New strategy in tumor treatment
A new strategy proposed by researchers at Dartmouth Medical School and Amtek, Hanover, NH may treat tumors that do not respond to conventional treatment.
DKK-3 and WIF-1: Proteins related to liver cancer development?
Liver cancer is one of the most fatal human malignancies and the third most frequent cause of tumor-related death, about half a million people globally each year.
Mayo researchers discover mechanism of cell type-specific signaling in tumor development
Mayo Clinic researchers have discovered the mechanisms behind two key checkpoints in cell growth and development - factors that may ultimately allow investigators to benchmark progression of tumor cells or stop them from further development. The findings appear in the current online issue of Developmental Cell.
NCI-Penn Collaboration Finds Targeted Immune Cells Shrink Tumors in Mice
Researchers have generated altered immune cells that are able to shrink, and in some cases eradicate, large tumors in mice.
New research group offers hope to asbestosis sufferers
The Asbestos Research Group, offering hope to sufferers of asbestos-related diseases, was launched at The Wesley Research Institute today.
First biomarker discovered that predicts prostate cancer outcome
Mayo Clinic researchers have identified the first immune molecule that appears to play a role in prostate cancer development and in predicting cancer recurrence and progression after surgery.
Frog molecule could provide drug treatment for brain tumours
Known as Amphinase, the molecule recognises the sugary coating found on a tumour cell and binds to its surface before invading the cell and inactivating the RNA it contains, causing the tumour to die.
Talcum powder stunts growth of lung tumors
Talcum powder has been used for generations to soothe babies' diaper rash and freshen women's faces. But University of Florida researchers report the household product has an additional healing power: The ability to stunt cancer growth by cutting the flow of blood to metastatic lung tumors.
Asbestos disease projections too low
Current predictions of the future incidence of asbestos-related disease have been substantially underestimated, according to new modelling to be presented in Melbourne today by an epidemiologist from The Australian National University.
More Mesothelioma Current Events and Mesothelioma News Articles
 |
Surviving Mesothelioma and Other Cancers: A Patient's Guide by Paul Kraus (Author) |
 |
100 Questions & Answers About Mesothelioma, Second Edition by Harvey I. Pass (Author), John A. Dingell (Author) Whether you re a newly diagnosed Mesothelioma patient, a survivor, or a friend or relative of either, this book offers help. Completely revised and updated for this second edition, this is the only book to provide the doctor s and patient s views. 100 Questions & Answers About Mesothelioma, Second Edition gives you authoritative, practical answers to your questions about treatment options, post-treatment quality of life, sources of support, legal options, and much more. This outstanding team of authors led by a world-class lung disease expert and including an insider s comments from the wife and caregiver of a patient provides an invaluable resource for anyone coping with the physical and emotional turmoil of this frightening disease. |
 |
They Said Months. I Chose Years! A Mesothelioma Survivor's Story by J.R. O'Connor (Author) In October 2001, James O'Connor was diagnosed with mesothelioma, the asbestos caused cancer. His prognosis was less than a year to live. Surgery was not possible because of the position of the tumor and chemotherapy would decrease his quality of life and not significantly improve his length of life. His oncologist suggested that he take his wife on a cruise and start hospice care upon his return. James rejected the idea. Instead he was determined to survive this cancer. Working with other professional clinicians, he formulated a regimen of over 100 supplements a day, changed his diet, practiced mind-body medicine, and relied on his own discipline to see him through the difficult times ahead. More than six years later, James is alive and active. He enjoys his life and continues his... |
 |
Malignant Mesothelioma: Pathogenesis, Diagnosis, and Translational Therapies by Harvey I. Pass (Editor), Nicholas Vogelzang (Editor), Michele Carbone (Editor) Malignant mesothelioma is a rare form of cancer in which the cancer cells are found in the sac lining the chest (pleura) or abdomen (peritoneum). This lethal disease is associated with asbestos and has vast economic and legal implications. As the disease takes approximately twenty years to manifest itself in humans, a wave of diagnoses are expected in the near future. In the United States alone, an estimated 3,500 - 4,000 patients are diagnosed with mesothelioma annually, and it is estimated that over the next 35 years, more than 250,000 people in Western Europe will be diagnosed with the disease. Malignant Mesothelioma, edited by internationally recognized experts in the field, is a comprehensive text that relates science, pathology, clinical aspects and therapy for mesothelioma under... |
|
Mesothelioma by MOHD HAFIZ BIN SAAD This blog discuss about Mesothelioma,cause,disease and much moreKindle blogs are fully downloaded onto your Kindle so you can read them even when you're not wirelessly connected. And unlike RSS readers which often only provide headlines, blogs on Kindle give you full text content and images, and are updated wirelessly throughout the day. | |
 |
Malignant Pleural Mesothelioma by Kenneth O'Byrne (Editor), Valerie Rusch (Editor) Malignant pleural mesothelioma, a malignancy due largely to asbestos exposure, represents an increasingly common challenge to clinical and medical oncologists, respiratory physicians, and cardiothoracic surgeons, as well as researchers in the field. The disease has yet to reach its peak and is expected to kill over 100,000 people worldwide. As malignant pleural mesothelioma gains in profile, Kenneth O'Byrne and Valerie Rusch present a comprehensive overview of the subject, aimed at all health care professionals who come into contact with patients with the disease. The book includes chapters on epidemiology, diagnosis, histopathology, radiology, surgery, chemotherapy, immune therapy, radiotherapy, and palliative medicine, written by an international team of contributors. A molecular... |
 |
Mesothelioma Awareness Ribbon Mouse Pad by MyHeritageWear.com The Mesothelioma Ribbon proudly displayed on a mouse pad. There is no better way to achieve awareness for the meaning of the Mesothelioma Ribbon than to display it on your mouse pad for everyone to see. The mouse pad measures at 9.25 x 7.75, it is machine washable, and the colors will not fade or run. Start gaining awareness today by presenting your Mesothelioma Ribbon mouse pad at work or at home. It is certain to keep your mouse rolling in style all while gaining support and awareness! |
 |
Beating Mesothelioma Together Long Sleeve T-shirt Large White by Shop Zeus |
 |
Mesothelioma by Bruce W S Robinson (Editor), A Philippe Chahinian (Editor) (Martin Dunitz) Second author is with Mount Sinai Hospital, New York, NY. Presents a state-of-the-art review of this condition, from laboratory to the bedside, from diagnostic procedures through treatment, and from imaging and early detection to medico-legal issues. For clinicians and scientists and members of the legal profession. |
 |
Cure Mesothelioma Mug by Design a Product LLC Text on mug: Cure Mesothelioma * Custom coffee mugs are dishwasher-safe and microwave-safe. Colors are permanently baked into the mug''s surface. * If you have new ideas or need help selecting text for your custom coffee mugs please contact us. * Size: 11 oz. capacity ceramic coffee mug. |
| © 2009 BrightSurf.com |